Advertisement

 

 

Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma.

Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma.
Author Information (click to view)

Wasilewski A, Mohile N,


Wasilewski A, Mohile N, (click to view)

Wasilewski A, Mohile N,

Advertisement

CNS oncology 2018 04 09() doi 10.2217/cns-2017-0039

Abstract
BACKGROUND
Adult pilocytic astrocytomas are rare and highly vascular tumors.

AIM
We hypothesized that they may be uniquely responsive to bevacizumab (BEV).

PATIENTS
We present four adult patients with pathologically diagnosed WHO grade I pilocytic astrocytoma who had robust and durable responses to BEV at time of recurrence. Three patients developed radiographic changes on MRI, consistent with progressive disease based on response assessment in neuro-oncology criteria. Median time to recurrence was 8.5 months.

METHODS
All patients were treated with six cycles of BEV for recurrence.

RESULTS
At the end of treatment, all patients had achieved a clinical and radiographic response. Median follow-up time after BEV is 20.5 months.

CONCLUSION
This suggests that BEV may have true antitumor activity in adult pilocytic astrocytomas and may be important for achieving durable disease control.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen + 10 =

[ HIDE/SHOW ]